Ruth E. Brown
Research Subjects
Ruth E. Brown has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
D. Theodoratou
UBC Health Care Analytics Group, London, UK
1 shared publication- Dafna D. Gladman
Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
1 shared publication J. G. Breugelmans
Sanofi – Pasteur MSD, France
1 shared publicationJyoti Nandi
1 shared publicationS. Bénard
Sanofi – Pasteur MSD, France
1 shared publicationSean Stern
United BioSource Corporation, Bethesda, USA
1 shared publication
Latest Publications
- 10 May 2012
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 14 (3) , 507-514
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
Purpose To determine the cost effectiveness of lenalidomide plus dexamethasone (LEN/DEX) versus DEX alone in managing multiple myeloma (MM) patients who have failed one prior therapy. Materials and Methods An individual simulation model was designed to capture the costs and outcomes of LEN/DEX versus DEX therapy in relapsed refractory MM patients. MM009/010 efficacy data were adjusted for treatment cross-over and extrapolated to patient lifetime. Resource use for MM disease progression and adverse events were obtained from expert physicians and costed from the perspective of the National Health Service (England and UK) and included a patient access scheme for LEN. Utility values were obtained from published literature. Results The simulation model estimated an incremental improvement in time to progression of 9.5 months, an additional 3.2 life-years, and 2.2 quality adjusted life years (QALY) for LEN/DEX compared to DEX alone. Including the costs of therapy with the patient access scheme, adverse events, and disease follow-up, the incremental cost effectiveness ratio was £30,153/QALY for LEN/DEX compared to DEX alone in MM patients who have failed one prior therapy. Conclusion LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment.
- 10 May 2012
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 14 (3) , 507-514
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales
Purpose To determine the cost effectiveness of lenalidomide plus dexamethasone (LEN/DEX) versus DEX alone in managing multiple myeloma (MM) patients who have failed one prior therapy. Materials and Methods An individual simulation model was designed to capture the costs and outcomes of LEN/DEX versus DEX therapy in relapsed refractory MM patients. MM009/010 efficacy data were adjusted for treatment cross-over and extrapolated to patient lifetime. Resource use for MM disease progression and adverse events were obtained from expert physicians and costed from the perspective of the National Health Service (England and UK) and included a patient access scheme for LEN. Utility values were obtained from published literature. Results The simulation model estimated an incremental improvement in time to progression of 9.5 months, an additional 3.2 life-years, and 2.2 quality adjusted life years (QALY) for LEN/DEX compared to DEX alone. Including the costs of therapy with the patient access scheme, adverse events, and disease follow-up, the incremental cost effectiveness ratio was £30,153/QALY for LEN/DEX compared to DEX alone in MM patients who have failed one prior therapy. Conclusion LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment.
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 10 (4) , 371-4
Cost-effectiveness of high-dose intravenous esomeprazole in patients with peptic ulcer bleeding in the USA and Europe.
Peptic ulcer bleeding (PUB) is life-threatening and associated with high healthcare costs. Clinical outcomes in PUB depend largely on the risk of rebleeding. Recent data indicate that intravenous proton pump inhibitors (PPIs) reduce rebleeds, the need for surgery and repeat endoscopic treatment. From a policy perspective, it is important to assess the cost-effectiveness of this treatment. Accordingly, a decision-tree model published by Barkun et al. evaluated the costs and benefits of high-dose intravenous esomeprazole in preventing rebleeds in patients with PUB based on data from a multinational, randomized clinical trial comparing this therapeutic approach to intravenous placebo. The results indicate that esomeprazole is cost effective in the USA and Sweden, and cost saving in Spain. These findings agree with most other analyses of intravenous PPIs used in PUB patients at high risk for bleeds. The therapeutic approach provides increased benefits to patients at a relatively small additional cost.
- 1 August 2010
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 10 (4) , 371-4
Cost-effectiveness of high-dose intravenous esomeprazole in patients with peptic ulcer bleeding in the USA and Europe.
Peptic ulcer bleeding (PUB) is life-threatening and associated with high healthcare costs. Clinical outcomes in PUB depend largely on the risk of rebleeding. Recent data indicate that intravenous proton pump inhibitors (PPIs) reduce rebleeds, the need for surgery and repeat endoscopic treatment. From a policy perspective, it is important to assess the cost-effectiveness of this treatment. Accordingly, a decision-tree model published by Barkun et al. evaluated the costs and benefits of high-dose intravenous esomeprazole in preventing rebleeds in patients with PUB based on data from a multinational, randomized clinical trial comparing this therapeutic approach to intravenous placebo. The results indicate that esomeprazole is cost effective in the USA and Sweden, and cost saving in Spain. These findings agree with most other analyses of intravenous PPIs used in PUB patients at high risk for bleeds. The therapeutic approach provides increased benefits to patients at a relatively small additional cost.
- 1 April 2008
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 8 (2) , 111-125
Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease
Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. It alleviates the symptoms of these diseases, prevents disease progression in some patients and, in the case of Crohn’s disease, induces and maintains remission. Compared with traditional disease-modifying antirheumatic drugs that offer significantly less benefit, adalimumab is much more costly. However, most studies to date demonstrate the cost-effectiveness of adalimumab treatment. Cost-effectiveness data for newer indications of adalimumab, including ankylosing spondylitis and Crohn’s disease, are needed. As longer term data for adalimumab become available, the cost-effectiveness data will have greater precision.
- 1 April 2008
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 8 (2) , 111-125
Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease
Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. It alleviates the symptoms of these diseases, prevents disease progression in some patients and, in the case of Crohn’s disease, induces and maintains remission. Compared with traditional disease-modifying antirheumatic drugs that offer significantly less benefit, adalimumab is much more costly. However, most studies to date demonstrate the cost-effectiveness of adalimumab treatment. Cost-effectiveness data for newer indications of adalimumab, including ankylosing spondylitis and Crohn’s disease, are needed. As longer term data for adalimumab become available, the cost-effectiveness data will have greater precision.
- 17 February 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (4) , 663-670
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
Objective: Infection with human Papillomavirus (HPV) is a necessary cause of cervical cancer (CC) and genital warts (GW). HPV vaccination studies have shown excellent efficacy against HPV-induced lesions. To assess the cost-effectiveness of a HPV quadrivalent (6, 11, 16 and 18) vaccine it is necessary to estimate the costs of managing current levels of HPV-related diseases. This study estimates the annual 2003 expenditures in the UK for CC screening, follow-up of abnormal findings, CC treatment and GW treatment.Design and methods: CC screening programmes provided the annual number of screening tests, their results and use of colposcopy procedures in women with abnormal findings. Incident CC cases and hospital admissions for CC in 2003 were used to estimate CC costs. Health Protection Agency data provided the annual number of new, recurrent or persistent cases of GW treated in Genitourinary Medicine (GUM) clinics. Treatment patterns for managing GW were estimated by GUM clinicians. The annual physi...
- 17 February 2006
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (4) , 663-670
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
Objective: Infection with human Papillomavirus (HPV) is a necessary cause of cervical cancer (CC) and genital warts (GW). HPV vaccination studies have shown excellent efficacy against HPV-induced lesions. To assess the cost-effectiveness of a HPV quadrivalent (6, 11, 16 and 18) vaccine it is necessary to estimate the costs of managing current levels of HPV-related diseases. This study estimates the annual 2003 expenditures in the UK for CC screening, follow-up of abnormal findings, CC treatment and GW treatment.Design and methods: CC screening programmes provided the annual number of screening tests, their results and use of colposcopy procedures in women with abnormal findings. Incident CC cases and hospital admissions for CC in 2003 were used to estimate CC costs. Health Protection Agency data provided the annual number of new, recurrent or persistent cases of GW treated in Genitourinary Medicine (GUM) clinics. Treatment patterns for managing GW were estimated by GUM clinicians. The annual physi...